KALA - KALA BIO, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

KALA

KALA BIO, INC.

NASDAQ

$0.69

▼ DOWN 15.02% (-0.12)

KEY STATISTICS

Market Cap$13.35 M

52w High$1030.00

52w Low$0.59

Dividend Yield—

Frequency—

P/E-0.24

Volume2.41M

Shares Out.19.34M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Avi Minkowitz

COMPENSATION 2026

Salary$709,394

Stock Awards$100,100

Incentive Plan Pay$0

All Other Comp.$6,120

Total$1,491,187

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 20, 2017

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$35.00

Target Low$1.50

Target Median$18.25

Target Consensus$18.25

UPCOMING EARNINGS

DateNov 10, 2026

DayTuesday

Rev. Est.—

NOV

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2026-05-11	Reverse	1:50
2022-10-21	Reverse	1:50
2022-08-26	Forward	2:1

PRICE

$0.69 ▼ DOWN 15.02% (−$0.12)

OVERLAYS

About KALA BIO, Inc.

https://www.kalarx.com ↗

Kala Bio, founded in 2009 in Arlington, MA, develops biopharmaceuticals using proprietary mucus-penetrating nanoparticles, initially targeting ophthalmic diseases. Co-founders include Justin Hanes, Robert S. Langer, and Colin R. Gardner.

INDUSTRY

Biotechnology

A PRODUCT KALA BIO, INC. IS KNOWN FOR

KPI-012

KPI-012, a cell-free therapy from mesenchymal stem cell secretomes, targets severe ocular diseases like PCED. It is KALA BIO's lead candidate, reflecting their shift after selling previous assets.